PBM Reporting Transparency Act

Bill 118 s 2493, also known as the PBM Reporting Transparency Act, is a piece of legislation currently being considered by the US Congress. The bill aims to increase transparency in the pharmaceutical industry by requiring pharmacy benefit managers (PBMs) to report certain information to the Department of Health and Human Services.

Under the provisions of the bill, PBMs would be required to report information on the rebates, discounts, and other price concessions they receive from drug manufacturers. This information would then be made publicly available on a website maintained by the Department of Health and Human Services.

The bill also includes provisions aimed at increasing competition in the pharmaceutical industry. It would require PBMs to disclose any conflicts of interest they may have, such as financial relationships with drug manufacturers. Additionally, the bill would prohibit PBMs from engaging in certain anti-competitive practices, such as steering patients towards certain drugs based on financial incentives. Overall, the PBM Reporting Transparency Act seeks to increase transparency and accountability in the pharmaceutical industry, with the goal of lowering drug prices and improving access to affordable medications for all Americans. The bill is currently being debated in Congress, with supporters arguing that it will help to level the playing field for consumers, while opponents raise concerns about the potential impact on the pharmaceutical industry.